PHRI Properties

By Ben Butkus Biosearch Technologies said today that it has acquired worldwide rights from the University of Medicine and Dentistry of New Jersey to patents covering "non-FRET" nucleic acid probe technology.

Princeton University, Point-2-Point Genomics, PHRI at UMDNJ/NJMS, and NuGen Technologies awarded US patents.

The UK-based company will offer the toolkit through a single license that combines IP it licensed from Brandeis University and PHRI Properties, the tech-transfer arm of the University of Medicine and Dentistry of New Jersey.